Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis to present cancer data at ASH and SABCS

Novartis to present cancer data at ASH and SABCS

5th December 2013

Novartis has announced that it will be presenting data from its clinical research pipeline at two major scientific symposia taking place this month.

The company will be attending both the annual meeting of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS), with more than 240 abstracts to be presented.

Key scientific evidence for targeted treatments in chronic myeloid leukaemia, myelofibrosis and advanced breast cancer will be shared, as well as emerging information on various pipeline compounds.

Drugs that will be showcased during the two events include Tasigna, Jakavi, Exjade and Afinitor, as well as the investigational PKC412, CTL019, LDE225, LBH589, BKM120 and BYL719.

Herve Hoppenot, president of Novartis Oncology, said: "We are presenting new long-term findings on well-established, targeted therapies while also reporting early data on innovative treatment approaches and compounds in areas of high unmet patient need."

Last month, the company highlighted the growth of its oncology division as being a crucial part of its future growth prospects and business strategy.ADNFCR-8000103-ID-801669053-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.